Regeneron Gets CHMP Backing for Covid-19 Cocktail
November 11 2021 - 11:57AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. on Thursday said the European
Medicines Agency's Committee for Medicinal Products for Human Use
recommended approval of its antibody cocktail to treat and prevent
Covid-19.
The Tarrytown, N.Y., biotechnology company said the CHMP's
positive opinion covers the drug for the treatment of
non-hospitalized Covid-19 patients ages 12 and up who don't need
supplemental oxygen who are at increased risk of progressing to
severe Covid-19, and for the prevention of the disease.
Regeneron invented the antibody cocktail, known as REGEN-COV in
the U.S. and Ronapreve elsewhere around the world, and is
collaborating with Swiss pharmaceutical company Roche Holding AG,
which is primarily responsible for development and distribution
outside the U.S.
Regeneron said it expects a decision from the European
Commission, which generally follows the CHMP's advice, in the near
future.
The U.S. Food and Drug Administration previously granted
emergency-use authorization for REGEN-COV in certain post-exposure
preventative settings and as a treatment for non-hospitalized
patients with mild to moderate Covid-19 who are at high risk of
serious consequences from the disease.
The agency last month granted priority review to Regeneron's
application for full approval of the drug for non-hospitalized
patients. Regeneron said it expects to complete an FDA submission
focusing on hospitalized patients by the end of the year.
Regeneron earlier this week said a long-term study showed
REGEN-COV continued to provide strong protection against Covid-19
infection for eight months, reducing the risk of contracting the
disease by 81.6% compared with a placebo.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 11, 2021 11:42 ET (16:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024